Ania Jastreboff, M.D., Ph.D.

Stories

Retatrutide phase 3 trial shows 30% average weight loss at 104 weeks

Directs the Yale Obesity Research Center (Y-Weight)

Eli Lilly's obesity drug retatrutide met its goals in two late-stage trials published in late September. The 12 mg dose produced 30.3% average weight loss over 104 weeks in adults with obesity, per Lilly's topline (the NEJM paper's primary 80-week endpoint was 25.0%), a level once seen mainly after bariatric surgery. In 1,152 adults with type 2 diabetes, the same dose cut weight 18.8% at 80 weeks, and 79% reached an HbA1c of 6.5% or lower.

Updated Oct 18

Notable Quotes

It was impressive to see that every dose of retatrutide resulted in clinically meaningful weight reduction for nearly all participants, and people with severe obesity on the highest dose lost on average 30% of their body weight over two years.

from Retatrutide phase 3 trial shows 30% average weight loss at 104 weeks · Updated Oct 18

For patients I see in clinic, retatrutide may potentially be a highly impactful future tool to treat their obesity and transform their health trajectory.

from Retatrutide phase 3 trial shows 30% average weight loss at 104 weeks · Updated Oct 18